Month: September 2023

Initial primary endpoint data anticipated in late 2023 or early Q1 2024 WALTHAM, Mass., Sept. 11, 2023 (GLOBE NEWSWIRE) — Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that the first participant has been dosed in the CANOPY Phase 3 pivotal clinical trial of VYD222, a broadly neutralizing, half-life extended monoclonal antibody, for the prevention of symptomatic COVID-19. This clinical trial is designed to rapidly generate the clinical data needed to support a potential emergency use authorization (EUA) submission for VYD222. CANOPY is expected to enroll approximately 750 participants in two cohorts (A and B) including 300 individuals who are significantly immunocompromised. “The initiation of the CANOPY pivotal...

OTTAWA and HAWTHORNE, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) — Telesat (NASDAQ and TSX: TSAT), one of the world’s largest and most innovative satellite operators, and SpaceX, which designs, manufactures and launches the world’s most advanced rockets and spacecraft, today announced a multi-launch agreement to deliver the Telesat Lightspeed constellation to Low Earth Orbit (LEO). Telesat has contracted 14 launches on SpaceX’s Falcon 9, the most reliable and only reusable orbital rocket flying today, which will carry up to 18 Telesat Lightspeed satellites to LEO per launch. The launch campaign is scheduled to commence in 2026 and will take advantage of SpaceX’s high launch cadence to rapidly deploy the satellites and enable Telesat to begin providing global service in 2027. Launches for the campaign will lift off from SpaceX’s launch...

MISSISSAUGA, Ontario, Sept. 11, 2023 (GLOBE NEWSWIRE) — Next Hydrogen Solutions Inc. (“Next Hydrogen”) (TSXV:NXH, OTC:NXHSF) and Casale SA (“Casale”), have signed a non-exclusive memorandum of understanding to develop green ammonia and methanol systems that integrate Next Hydrogen’s electrolysis technology and products. Under this agreement, the companies will bring together their collective experience and capabilities to accelerate and scale-up green ammonia and methanol plants connected to renewable energy sources. Next Hydrogen has deep expertise in electrolysis and is launching its next generation of large-scale, low-cost green hydrogen systems. Casale has a strong track record of technologies innovation in fertilizer production processes and plants, and is ideally positioned to exploit the advantages of Next Hydrogen’s new...

Valentin Curt, MDSenior Vice President, Clinical Drug Development and Interim Chief Medical Officer at Eagle Pharmaceuticals— CAL02 is a unique therapeutic agent that is designed to work differently from antibiotics, aiming to disarm an infectious pathogen’s virulence factors to reduce damage and mitigate disease —— The first-in-human study showed positive safety and efficacy when added to standard of care in patients with severe community-acquired bacterial pneumonia —WOODCLIFF LAKE, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) — Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that its abstract describing the global in-progress Phase 2 study of CAL02, a first-in-class, broad-spectrum, anti-virulence agent under development as an adjunct to antibiotic therapy for...

MELBOURNE, Australia, Sept. 11, 2023 (GLOBE NEWSWIRE) — Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting virtually at the H.C. Wainwright 25th Annual Global Investment Conference on September 11th. The webcast to this presentation will be available here at 7am Eastern Daylight Time / 9pm Australian Eastern Standard time on September 11th. A copy of the presentation being made at the H.C. Wainwright 25th Annual Global Investment Conference is available on the Company’s website. https://www.immuron.com.au/corporate-presentations/ This release has been authorised by the directors of Immuron Limited. COMPANY CONTACT: Steven LydeamoreChief Executive OfficerPh: +61 (0)3 9824 5254info@immuron.com   About...